Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen reported that the PALISADE-4 Phase 3 trial of fasedienol failed to meet its primary endpoint, with the drug showing no statistically significant improvement over placebo on the SUDS score in the overall population (p=0.427). A post-hoc analysis of patients with very severe social anxiety disorder (LSAS >=95) showed a nominally statistically significant improvement (p=0.036), and safety data remained consistent with previous trials.
Key figures
- Drug Name
- Fasedienol
- Phase Of Trial
- Phase 3
- Subgroup n
- 123
- Cash runway
- into 2027
- Primary p value
- 0.427
- Subgroup p value
- 0.036
- Primary population n
- 238
- Subgroup baseline lsass threshold
- 95
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.